ReviewInternational journal of obesity (2005)2026
A time bridge for obesity care: protein monitoring adds a timing layer to the EASO pathway while preserving the Lancet Commission definition.
Review in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Association for the Study of Obesity (EASO) frames obesity care around staged, target-driven decisions. The Lancet Diabetes & Endocrinology Commission provides a disease definition-clinical obesity requires objective dysfunction- and distinguishes preventive strategies for preclinical obesity from therapeutic strategies for clinical obesity. Continuous protein monitoring (CPM) refers to wearable or minimally invasive sensors that repeatedly measure short panels of proteins in interstitial fluid or blood and track within-person trends over time. We hypothesize that CPM could help stratify risk and guide the timing of preventive intervention in preclinical obesity (excess adiposity, preserved function), and trigger timely escalation within the EASO pathway without changing the Commission's diagnostic criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.